- Combining Lilly and Amylin drug with insulin intake found to promote weight loss
- Amylin trims losses in Q4, full-year results
- Decision Resources: Type 2 diabetes market in China to nearly double by 2014
- Adherence among chronic disease patients can lead to big savings
- Fatty liver may impose diabetes risk
BURLINGTON, Mass. — Eli Lilly’s and Amylin Pharmaceuticals’ Type 2 diabetes drug, Bydureon, appears to work better at promoting weight loss than drugs made by Takeda and Merck, but it could face a challenger of its own.
Market research firm Decision Resources found that while Lilly’s and Amylin’s Bydureon (exenatide) was better able to promote weight loss among patients than Takeda’s Actos (pioglitazone hydrochloride) and Merck’s Januvia (sitagliptin), Bristol-Myers Squibb’s and AstraZeneca’s investigative drug dapagliflozin could challenge Bydureon in this aspect as well.
Decision Resources said the Type 2 diabetes market would experience strong growth over the next decade, increasing from $20.5 billion in 2009 to $36 billion in 2019 in the United States, United Kingdom, France, Germany, Italy, Spain and Japan.